Paritaprevir
- Generic Name
- Paritaprevir
- Brand Names
- Viekira Pak
- Drug Type
- Small Molecule
- Chemical Formula
- C40H43N7O7S
- CAS Number
- 1216941-48-8
- Unique Ingredient Identifier
- OU2YM37K86
- Background
Paritaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% ...
- Indication
When used within the fixed-dose combination product with Ombitasvir, Dasabuvir, and Ritonavir as the FDA-approved product Viekira Pak, paritaprevir is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrh...
- Associated Conditions
- Chronic hepatitis C genotype 1a with compensated cirrhosis, Chronic hepatitis C genotype 1a without cirrhosis, Chronic hepatitis C genotype 1b with compensated cirrhosis, Chronic hepatitis C genotype 1b without cirrhosis, Chronic hepatitis C genotype 4 without cirrhosis
- Associated Therapies
- -
Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment
- Conditions
- Interventions
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Nova Scotia Health Authority
- Target Recruit Count
- 44
- Registration Number
- NCT02460133
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.